In 2017, the global diabetes market is anticipated to grow at a CAGR of 7.4% to reach US$90.7 billion in 2022 and US$137.7 billion in 2028. In terms of prevalence and incidence, China has the highest patient base (110.5 million), making it a battleground for pharmaceutical companies to find a position. A few key drivers are behind this. First, dramatic changes in lifestyle and an aging population will keep accelerating the spread of diabetes. Second, drug list expansions of reimbursement coverage will drive innovation for the next generation of anti-diabetes medicines. Third, pharmaceutical companies are now trying to diversify the features of therapeutic drugs, such as their half-life, mechanism of action, new concept of drug discovery, and so forth. In other words, diabetes medicine allows for more diversity on the discovery approach. Finally, new players are actively engaged in clinical trials in order to enter the market.
Project ID: DIA100
Keywords: Degenerative neurological disease drugs
Project employs its proprietary excipient library, BioChaperone®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism
Indications: Diabetes and other metabolic diseases
Stage: Clinical Phase III
Partnering Objective: Joint development, Commercial license
Project ID: DIA101
Keywords: Protease activator
Project develops innovative treatments for metabolic disorders, including type 2 diabetes and NASH. With our partner Sumitomo Dainippon Pharma, we are conducting a Phase 3 program for Imeglimin for type 2 diabetes in Japan. Roivant Sciences is responsible for Imeglimin’s development and commercialization outside of Sumitomo Dainippon Pharma’s territories, including the US and Europe. PXL770, a direct adenosine monophosphate-activated protein kinase activator, is in Phase 2a for NASH and has the potential to treat additional metabolic diseases. PXL065, a mitochondrial pyruvate carrier inhibitor, is in Phase 1 for NASH. Poxel also has earlier-stage programs for metabolic, specialty and rare diseases.
Indications: Type 2 diabetes, NASH non-alcoholic fatty liver
Stage: Phase III
Partnering Objective: Licensing